Puma Biotechnology, Inc.
PBYI
$7.17
$0.091.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.38% | -0.91% | -12.96% | 8.63% | 2.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.38% | -0.91% | -12.96% | 8.63% | 2.68% |
| Cost of Revenue | -9.66% | -9.70% | -34.56% | 11.67% | 6.71% |
| Gross Profit | 0.40% | 2.50% | -3.39% | 7.52% | 1.23% |
| SG&A Expenses | -5.72% | -11.62% | -16.86% | -22.44% | -14.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.14% | -4.23% | -15.25% | -3.81% | -2.28% |
| Operating Income | -20.84% | 20.45% | 1.62% | 135.86% | 40.03% |
| Income Before Tax | -8.99% | 48.47% | 25.33% | 319.97% | 93.35% |
| Income Tax Expenses | 177.05% | 175.61% | -525.61% | -558.28% | -628.11% |
| Earnings from Continuing Operations | -35.94% | 2.75% | 59.11% | 455.63% | 147.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.94% | 2.75% | 59.11% | 455.63% | 147.59% |
| EBIT | -20.84% | 20.45% | 1.62% | 135.86% | 40.03% |
| EBITDA | -16.63% | 15.45% | -2.95% | 79.88% | 23.95% |
| EPS Basic | -37.13% | 1.03% | 56.02% | 429.89% | 137.93% |
| Normalized Basic EPS | -10.71% | 46.05% | 19.49% | 278.38% | 79.21% |
| EPS Diluted | -38.68% | -0.62% | 59.60% | 462.82% | 145.34% |
| Normalized Diluted EPS | -11.96% | 44.56% | 19.36% | 281.99% | 80.15% |
| Average Basic Shares Outstanding | 2.67% | 2.77% | 2.92% | 3.03% | 3.12% |
| Average Diluted Shares Outstanding | 3.38% | 3.81% | 3.46% | 3.27% | 2.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |